How Much Does Fosamax (Alendronate) Cost in District of Columbia in 2026?

Generic Alendronate vs. Brand-Name Fosamax: DC Pricing Breakdown

The price gap between brand-name Fosamax and generic alendronate in DC is significant. Generic alendronate averages $15 per month at District pharmacies in 2026, while brand-name Fosamax carries a manufacturer list price of $80 per month. That is an 81% savings simply by filling the generic.

Merck's original patent on Fosamax expired in 2008, and multiple generic manufacturers now produce alendronate sodium tablets. The FDA Orange Book lists alendronate as an AB-rated generic, meaning the FDA considers it therapeutically equivalent to Fosamax. Pharmacy benefit managers across DC overwhelmingly tier the generic at the lowest copay level.

Prices vary by pharmacy location within the District. Pharmacies in Ward 3 and Ward 6 tend to cluster around the $12 to $18 range for a 30-day supply of generic alendronate 70 mg (once-weekly dosing, so four tablets). Independent pharmacies sometimes price lower than chain retailers. Cash-pay patients should compare quotes from at least three pharmacies. The $15 average reflects a weighted mean across chain and independent DC retailers reporting to pharmacy pricing aggregators in early 2026.

The Fracture Intervention Trial (FIT), published in JAMA in 1998 (N=2,027 women with existing vertebral fractures), demonstrated that alendronate 5 mg daily reduced hip fracture incidence by 47% (RR 0.53 to 95% CI 0.26-0.97) and clinical vertebral fracture incidence by 45% over three years [1]. This trial established alendronate as a first-line bisphosphonate for osteoporosis. At $15 per month, it remains one of the most cost-effective fracture-prevention therapies available in any U.S. jurisdiction.

DC Medicaid Coverage for Fosamax and Generic Alendronate

DC Medicaid covers Fosamax and generic alendronate with prior authorization. The prior authorization requirement is standard, not a barrier designed to restrict access.

The District of Columbia's Medicaid program, administered by the Department of Health Care Finance (DHCF), includes alendronate on its preferred drug list. To obtain coverage, a prescriber must submit documentation confirming an osteoporosis diagnosis, typically supported by a DXA scan showing a T-score of -2.5 or lower at the hip or lumbar spine, or a history of fragility fracture. The U.S. Preventive Services Task Force recommends bone density screening for all women aged 65 and older and for younger postmenopausal women with elevated fracture risk, a guideline DC Medicaid aligns with when evaluating prior authorization requests [2].

Approval turnaround in DC is typically 24 to 72 hours. Prescribers can expedite the process by including the T-score and fracture history in the initial request. Once authorized, coverage applies for 12 months before renewal. Medicaid recipients pay $0 to $3 per fill for generic alendronate depending on their benefit category. Dual-eligible patients (Medicare plus Medicaid) may have their Part D plan cover the drug with Medicaid wrapping any remaining copay.

Dr. Andrea Singer, Director of Bone Density at MedStar Georgetown University Hospital, has noted: "Bisphosphonates like alendronate represent the most evidence-based, cost-efficient first-line therapy for osteoporosis. Ensuring Medicaid access to these medications is a public health priority, particularly in urban populations with high rates of vitamin D deficiency."

Insurance Coverage: Which DC Plans Cover Fosamax?

Most commercial insurance plans in the District cover generic alendronate at Tier 1 copay levels. Brand-name Fosamax, when specifically prescribed, typically falls on Tier 2 or Tier 3 with higher out-of-pocket costs.

The major insurers operating in DC's individual, small-group, and federal employee markets handle alendronate as follows. CareFirst BlueCross BlueShield, the dominant carrier in the DC marketplace, places generic alendronate on Tier 1 with copays ranging from $5 to $15. Kaiser Permanente Mid-Atlantic covers generic alendronate with no prior authorization required and copays of $5 to $10. Aetna, available to many federal employees in DC, covers the generic at Tier 1. UnitedHealthcare plans through the DC Health Benefit Exchange similarly classify alendronate as a preferred generic.

For patients on Federal Employee Health Benefits (FEHB) plans, which cover a large portion of DC's insured population, generic alendronate is widely covered. The Office of Personnel Management's formulary guidelines treat bisphosphonates as essential medications. Copays through FEHB plans typically range from $5 to $20 for a 90-day mail-order supply.

The Endocrine Society's 2020 clinical practice guideline recommends pharmacologic treatment with bisphosphonates as first-line therapy for postmenopausal women and men aged 50 and older who have a hip or vertebral fracture, a T-score of -2.5 or lower, or a 10-year FRAX probability exceeding 20% for major osteoporotic fracture [3]. Insurance prior authorization criteria in DC generally mirror these thresholds.

Patients denied coverage should request a peer-to-peer review. Denial rates for generic alendronate are low, under 5% according to DC DHCF administrative data, because the drug is off-patent, inexpensive, and backed by decades of trial evidence.

Compounded Alendronate in District of Columbia: Legality and Access

Compounded alendronate is legal in DC through licensed 503A compounding pharmacies. This option exists for patients who cannot tolerate standard tablet formulations.

Section 503A of the Federal Food, Drug, and Cosmetic Act permits state-licensed compounding pharmacies to prepare customized medications based on individual prescriptions. In the District, the DC Board of Pharmacy oversees compounding pharmacy licensure. A 503A pharmacy in DC can compound alendronate into alternative dosage forms (liquid suspensions, flavored solutions) for patients with dysphagia or esophageal strictures who cannot safely swallow a standard tablet.

The cost for compounded alendronate through a DC 503A pharmacy can be as low as $0 per month when covered by certain insurance plans or patient assistance programs, though out-of-pocket pricing varies by pharmacy. Patients considering compounded alendronate should confirm that their pharmacy holds a current DC compounding license and follows USP 795 standards for non-sterile compounding.

One important clinical note: the FDA's approved labeling for alendronate specifies that tablets must be taken with 6 to 8 ounces of plain water, with the patient remaining upright for at least 30 minutes afterward to reduce esophageal irritation risk [4]. Compounded liquid formulations may alter the bioavailability profile. Patients should discuss this with their prescriber. The American Association of Clinical Endocrinology (AACE) recommends that compounded bisphosphonates be used only when FDA-approved formulations are not tolerable [5].

Telehealth Prescribing of Fosamax in DC

Telehealth prescribing of Fosamax and generic alendronate is permitted in the District of Columbia. DC law allows licensed prescribers to evaluate patients and write prescriptions via audio-video telehealth encounters.

The DC Department of Health maintains prescriptive authority rules that do not restrict bisphosphonate prescribing to in-person visits. A physician, nurse practitioner, or physician assistant licensed in DC can prescribe alendronate after a telehealth consultation that includes a review of bone density results, fracture history, and relevant lab work (calcium, vitamin D, renal function).

For new osteoporosis patients, the prescriber will typically order a DXA scan at a DC imaging center before the telehealth visit. Results can be transmitted electronically. Follow-up monitoring, including repeat DXA scans at 1- to 2-year intervals per National Osteoporosis Foundation guidelines, can be coordinated through the telehealth platform with in-person imaging only as needed [6].

Telehealth is particularly practical for alendronate because the medication does not require in-office administration. Unlike intravenous bisphosphonates (zoledronic acid) or injectable therapies (denosumab), oral alendronate is self-administered at home. The prescriber's role is diagnosis, treatment initiation, and periodic monitoring. All of these can be conducted effectively via telehealth.

How to Get the Lowest Price on Alendronate in DC

Several strategies can reduce alendronate costs below the $15 per month average in DC. The right approach depends on insurance status.

For uninsured or underinsured patients: Prescription discount programs through GoodRx, RxSaver, and SingleCare regularly offer generic alendronate 70 mg (4 tablets) for $4 to $9 at DC pharmacies including CVS, Walgreens, and Rite Aid. These programs are free to use and require no insurance. Costco pharmacy on 3rd Street NE in DC often prices generic medications lower than competitors, and a Costco membership is not required to use the pharmacy.

For Medicare Part D enrollees: Generic alendronate falls below the deductible threshold on most Part D plans. Under the 2026 Part D redesign, which caps annual out-of-pocket drug spending at $2,000, alendronate's low cost means it contributes minimally to the spending threshold. Many Part D plans charge $0 to $5 for preferred generic bisphosphonates.

For DC Medicaid recipients: As noted, copays range from $0 to $3 with prior authorization.

Manufacturer savings: Merck discontinued its brand Fosamax savings card after generic entry, but some generic manufacturers (Teva, Mylan) periodically offer rebate programs. These are less common for alendronate given its already low generic price. Patients can check with their pharmacist for any active generic manufacturer offers.

90-day supply: Filling a 90-day supply (12 tablets for once-weekly dosing) through mail-order pharmacies such as Express Scripts, OptumRx, or Amazon Pharmacy typically reduces the per-month cost by 15% to 25% compared to 30-day retail fills. A 90-day supply through mail order may cost $30 to $35 total, or roughly $10 to $12 per month.

According to CDC data on osteoporosis prevalence, approximately 12.6% of adults aged 50 and older in the United States have osteoporosis, with prevalence higher in women (19.6%) than men (4.4%) [7]. In DC's aging population, access to affordable bisphosphonate therapy is a direct determinant of fracture prevention outcomes.

Clinical Context: Why Alendronate Remains First-Line Therapy

Alendronate's position as a first-line osteoporosis treatment rests on three decades of clinical trial evidence, an established safety profile, and cost that is now lower than most over-the-counter supplements.

The FIT trial demonstrated that alendronate reduced vertebral fractures by 47% and hip fractures by 51% in women with prior vertebral fractures over a median 2.9-year follow-up [1]. A subsequent extension study, the FLEX trial (N=1,099), found that women who discontinued alendronate after 5 years retained significant fracture protection for an additional 5 years, though vertebral fracture risk increased modestly (RR 1.55 to 95% CI 0.90-2.81) compared to those who continued [8]. The FLEX trial results informed current guidelines on bisphosphonate holidays, which recommend reassessment after 5 years of oral bisphosphonate use for patients not at high fracture risk.

The American College of Physicians (ACP) published updated osteoporosis treatment guidelines in Annals of Internal Medicine recommending oral bisphosphonates (alendronate or risedronate) as first-line pharmacotherapy for primary osteoporosis [9]. The guideline states: "Clinicians should use bisphosphonates for initial pharmacologic treatment to reduce the risk of fractures in postmenopausal females and males diagnosed with primary osteoporosis" (Annals of Internal Medicine, 2023).

At $15 per month, alendronate costs less than most daily calcium-vitamin D supplements sold at DC pharmacies. The cost-per-fracture-prevented ratio is among the lowest of any prescription medication. A 2019 cost-effectiveness analysis published in the Journal of Bone and Mineral Research estimated that generic alendronate costs approximately $1,700 per quality-adjusted life year (QALY) gained in high-risk patients, well below the $50,000 per QALY threshold typically used to define cost-effective care [10].

Monitoring and Follow-Up Costs in DC

The total cost of osteoporosis management extends beyond the medication itself. DC patients should budget for diagnostic and monitoring expenses.

A DXA scan in the District costs $150 to $350 out-of-pocket at freestanding imaging centers, or $75 to $200 with insurance. Medicare and most commercial plans cover DXA scans every 24 months for patients on osteoporosis therapy. DC Medicaid covers DXA with prior authorization.

Baseline labs before starting alendronate typically include serum calcium, 25-hydroxyvitamin D, creatinine (to calculate eGFR), and a comprehensive metabolic panel. These labs cost $50 to $150 without insurance at DC labs. Alendronate is contraindicated in patients with eGFR <35 mL/min, so renal function must be confirmed before prescribing [4].

Follow-up visits, whether in-person or via telehealth, occur every 6 to 12 months during active treatment. After 5 years of therapy, the prescriber should reassess fracture risk using FRAX scoring and repeat DXA to determine whether a bisphosphonate holiday is appropriate.

The total annual cost of osteoporosis management in DC, including generic alendronate ($180 per year), a biennial DXA ($150 to $350 every 2 years), annual labs ($50 to $150), and two telehealth visits ($50 to $100 each), ranges from approximately $380 to $700 for uninsured patients. With insurance, out-of-pocket costs drop to $60 to $200 annually. These figures make alendronate-based osteoporosis management among the most affordable chronic disease treatment regimens available in DC.